Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Blood Substitutes
Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
May 18th, 2008
Northfield Laboratories Inc. (NASDAQ:NFLD). Northfield Laboratories Inc. issued the following statement in response to a May 21 publication in the Journal of the American Medical Association entitled Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis and the accompanying editorial released online today. "Meta-analyses that compare varied products under the umbrella of an entire class are a useful tool to raise questions that may merit answers with respect to the class," said Steven A. Gould, M.D., Chairman and Chief Executive Officer of Northfield Laboratories, Inc. "But it is important to note what meta-analyses...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
